ASEAN market entry for EU MDR certified SaMD — 2026 strategy guide

Why EU MDR is your ASEAN competitive advantage

Companies without international regulatory approvals face full technical reviews in every ASEAN market — often 12–24 months per country, with full documentation submissions in each. EU MDR CE mark changes this equation dramatically. Singapore HSA, Malaysia MDA, Thailand FDA, Philippines FDA, and Vietnam DAV all recognise EU Notified Body certificates as reference approvals that reduce or eliminate full independent technical review requirements.

The result: a company with EU MDR certification can realistically enter Singapore + Malaysia within 12 months, add Thailand and Philippines within 18 months, and reach five ASEAN markets within 24 months — while a company starting from scratch in each market would still be completing Singapore registration at that point.

Market 1: Singapore (your first entry, your hub)

Singapore's Health Sciences Authority (HSA) is the most EU MDR-compatible regulator in Asia. Its December 2025 GL-04 update aligns SaMD requirements with IEC 62304, ISO 14971:2019, and IMDRF guidance — the same standards underpinning your MDR technical file. HSA explicitly accepts EU Notified Body certificates as reference approvals in its evaluation process.

For Class B SaMD the target review timeline is 120–180 days from complete submission; Class C is 180–270 days. With EU MDR reference, submissions are typically treated as more complete and fewer queries are generated. Your Singapore-registered device enters the SMDR — the key to every downstream ASEAN market.

Key Singapore-specific requirements beyond EU MDR: ASEAN CSDT submission format, HSA-specific Declaration of Conformity, Singapore labelling (English sufficient for professional SaMD), and compliance with GL-04 Rev.4 cybersecurity provisions including OS end-of-life planning. For AI/ML SaMD, the revised Change Management Programme applies.

Market 2: Malaysia (three months after Singapore)

From March 2026, Malaysia's MDA permanently accepts SMDR-listed devices through the Verification Route (MDA/GD/0070). CAB review time: 30 working days. MDA registration: further 30 working days. Total: approximately 3 months from submitting to your Malaysian CAB. This makes Malaysia the fastest second-market entry in ASEAN for Singapore-registered devices.

Requirements: licensed Malaysian Authorised Representative with Establishment Licence and GDPMD certificate, Malaysian-format Declaration of Conformity, MDA product certificate number on labelling, CSDT dossier. For home-use devices, Bahasa Malaysia IFU translation is required — for professional SaMD, English is sufficient.

Market 3: Thailand (reference approval pathway)

Thailand's FDA (TFDA) accepts EU Notified Body certificates as reference approvals in its device registration process. New SaMD-specific guidelines were issued by TFDA in 2024, establishing three device classes for software and specifying documentation requirements including risk analysis, QMS certificates, and cybersecurity documentation for connected SaMD. The Malaysia–Thailand regulatory reliance pilot (February–April 2026) further strengthens the cross-market pathway: MDA-approved devices benefit from a shortened 30-day review in Thailand, and TFDA-approved devices receive expedited Malaysian review.

For SaMD Class 2 and 3, TFDA requires: product description, risk analysis per ISO 14971, QMS certificate (ISO 13485 or equivalent), registration history in reference markets (EU MDR certificate is ideal evidence), and cybersecurity documentation for connected software. Class 1 SaMD (lowest risk) benefits from Thailand's January 2025 auto-approval process for listed device categories.

Market 4: Philippines (reference approval fast-track)

The Philippine FDA accepts Singapore HSA approvals as a reference in its streamlined registration pathway for internationally-approved devices. This means your Singapore SMDR listing — built on your EU MDR foundation — directly supports Philippines registration. The Philippines medical device market is growing rapidly, with hospital digitisation and digital health investment driving SaMD demand.

Philippines FDA registration requires a licensed Philippine Importer/Distributor to act as your local representative. Documentation requirements for internationally-approved devices include the SMDR or equivalent certificate, technical documentation summary, and Philippines-specific labelling including a local importer address. Timeline for internationally-approved Class B/C devices: typically 6–12 months.

Market 5: Indonesia (ASEAN CSDT pathway)

Indonesia's Ministry of Health (Kemenkes) regulates medical devices through its Directorate General of Pharmaceutical and Medical Devices. All devices require a Distribution Permit (Izin Edar) before market entry. Indonesia uses the ASEAN Common Submission Dossier Template (CSDT) — the same format used for Singapore and Malaysia — which significantly reduces the documentation adaptation burden for companies already registered in other ASEAN markets.

Indonesia does not have a formal reliance programme for EU MDR certificates at the level of Singapore's HSA, but EU NB certificates are accepted as supporting evidence in the CSDT submission. Timeline for Class B/C devices: 9–18 months. Indonesia's market of 280 million people — approaching near-universal JKN health insurance coverage — makes it the highest-volume ASEAN market despite the longer timeline.

Market 6: Vietnam (expedited pathway for ASEAN-approved devices)

Vietnam's Drug Administration of Vietnam (DAV) has an expedited review pathway for devices already registered in ASEAN reference markets. Under Circular 05/2022, devices registered with Singapore HSA qualify for a shortened assessment. Vietnam is a rapidly growing digital health market with significant demand for clinical decision support and diagnostic AI software.

Vietnam registration requires a locally licensed Authorised Representative. Documentation must be translated into Vietnamese for certain sections. Timeline for internationally-approved devices using the expedited pathway: approximately 6–12 months.

Recommended sequencing — 24-month ASEAN plan

Months 1–9: Singapore. Submit to HSA immediately. Start your Malaysian and Philippine AR search in parallel — appointment takes time and you need them in place before those submissions open.

Months 9–12: Malaysia. Submit to Malaysian CAB immediately upon receiving SMDR listing. Use Verification Route. Target registration within 3 months of submission.

Months 12–18: Thailand + Philippines. Submit both simultaneously using your Singapore approval as reference. Thailand benefits from the TFDA-MDA reliance pilot if your device is MDA-registered.

Months 18–24: Indonesia + Vietnam. Use ASEAN CSDT documentation from earlier submissions. Indonesia for volume; Vietnam for growth market positioning.